Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received a notice of acceptance from the National Medical Products Administration for the new indication of SHR-A1811, a drug for treating HER2-positive breast cancer in patients previously treated with one or more anti-HER2 therapies, which has been included in the priority review process [1] Group 1 - The drug SHR-A1811 is intended for adult patients with locally advanced or metastatic HER2-positive breast cancer [1] - The acceptance of the new indication application indicates potential growth opportunities for the company in the oncology market [1] - The inclusion in the priority review process may expedite the approval timeline, enhancing the company's competitive position [1]